1
|
Sivamani Chidambaram R, Rajmohan S, Manickam S, Mallikarjuna R, Nalawade T, Saraf S. Efficacy of a Novel Computerized Aid in Designing Removable Partial Dentures. Cureus 2024; 16:e54581. [PMID: 38523922 PMCID: PMC10959473 DOI: 10.7759/cureus.54581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 02/11/2024] [Indexed: 03/26/2024] Open
Abstract
BACKGROUND The development of computerized aids for dental education offers potential benefits in teaching complex procedures, such as the design of removable partial dentures (RPDs). This study aimed to assess the efficacy of a novel computerized tool in enhancing the ability of both dental students and practicing dentists to design RPDs, as well as to evaluate its utility as an interactive educational instrument. METHODS A cohort comprising a total of 75 individuals (25 practicing dentists and 50 undergraduate dental students) was enlisted. Participants were introduced to an online interactive application tailored for the design of RPDs. They were tasked with resolving clinical scenarios that necessitated the formulation of an RPD. Throughout the exercise, users were provided with hints addressing errors made during the process, fostering self-directed learning for improved RPD design. Post-interaction, the perceptions of both dentists and students regarding the tool were gauged through a comprehensive questionnaire. RESULTS The deployment of the online interactive application demonstrated significant promise in the effective design of RPDs, facilitated by self-directed learning. It also appeared to enhance the proficiency of practicing dentists in formulating partial dentures. CONCLUSION The computerized aid evaluated in this study provided an effective platform for both dental education and practice. It not only supported self-directed learning in the design of RPDs but also improved the efficiency of professional dentists in their clinical design work.
Collapse
Affiliation(s)
| | - Sudha Rajmohan
- Department of Preclinical Conservative Dentistry, Oman Dental College, Muscat, OMN
| | | | - Rachappa Mallikarjuna
- Department of Pedodontics and Preventive Dentistry, Oman Dental College, Muscat, OMN
| | - Triveni Nalawade
- Department of Pedodontics and Preventive Dentistry, Oman Dental College, Muscat, OMN
| | - Sanjay Saraf
- Department of Oral Biology, Oman Dental College, Muscat, OMN
| |
Collapse
|
2
|
Crabtree TS, Griffin TP, Yap YW, Narendran P, Gallen G, Furlong N, Cranston I, Chakera A, Philbey C, Karamat MA, Saraf S, Kamaruddin S, Gurnell E, Chapman A, Hussain S, Elliott J, Leelarathna L, Ryder RE, Hammond P, Lumb A, Choudhary P, Wilmot EG. Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study. Diabetes Care 2023; 46:1831-1838. [PMID: 37566697 PMCID: PMC10516256 DOI: 10.2337/dc23-0635] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 07/24/2023] [Indexed: 08/13/2023]
Abstract
OBJECTIVE We explored longitudinal changes associated with switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy. RESEARCH DESIGN AND METHODS We undertook a pragmatic, preplanned observational study of participants included in the National Health Service England closed-loop pilot. Adults using isCGM and insulin pump across 31 diabetes centers in England with an HbA1c ≥8.5% who were willing to commence HCL therapy were included. Outcomes included change in HbA1c, sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), acute event rates, and user opinion of HCL. RESULTS In total, 570 HCL users were included (median age 40 [IQR 29-50] years, 67% female, and 85% White). Mean baseline HbA1c was 9.4 ± 0.9% (78.9 ± 9.1 mmol/mol) with a median follow-up of 5.1 (IQR 3.9-6.6) months. Of 520 users continuing HCL at follow-up, mean adjusted HbA1c reduced by 1.7% (95% CI 1.5, 1.8; P < 0.0001) (18.1 mmol/mol [95% CI 16.6, 19.6]; P < 0.0001). Time in range (70-180 mg/dL) increased from 34.2 to 61.9% (P < 0.001). Individuals with HbA1c of ≤58 mmol/mol rose from 0 to 39.4% (P < 0.0001), and those achieving ≥70% glucose time in range and <4% time below range increased from 0.8 to 28.2% (P < 0.0001). Almost all participants rated HCL therapy as having a positive impact on quality of life (94.7% [540 of 570]). CONCLUSIONS Use of HCL is associated with improvements in HbA1c, time in range, hypoglycemia, and diabetes-related distress and quality of life in people with type 1 diabetes in the real world.
Collapse
Affiliation(s)
- Thomas S.J. Crabtree
- Department of Diabetes and Endocrinology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trusts, Derby, U.K
- School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, U.K
| | - Tomás P. Griffin
- Leicester Diabetes Center, University Hospitals of Leicester, Leicester, U.K
- Diabetes Research Center, College of Health Sciences, University of Leicester, Leicester, U.K
| | - Yew W. Yap
- Department of Diabetes and Endocrinology, Aintree University Hospital, Liverpool University Hospital NHS Foundation Trust, Liverpool, U.K
| | - Parth Narendran
- Department of Diabetes, The Queen Elizabeth Hospital, Birmingham, Birmingham, U.K
- The Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, U.K
| | | | - Niall Furlong
- Diabetes Center, St. Helens Hospital, St. Helens and Knowsley Teaching Hospitals NHS Trust, Merseyside, U.K
| | - Iain Cranston
- Academic Department of Endocrinology and Diabetes Portsmouth Hospitals University NHS Trust, Queen Alexandra Hospital, Portsmouth, U.K
| | - Ali Chakera
- Department of Diabetes and Endocrinology, University Hospitals Sussex, Brighton, U.K
- Brighton and Sussex Medical School, Brighton, U.K
| | - Chris Philbey
- Department of Diabetes and Endocrinology, Harrogate and District NHS Trust, Harrogate, U.K
| | - Muhammad Ali Karamat
- Department of Diabetes and Endocrinology, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K
| | - Sanjay Saraf
- Department of Diabetes and Endocrinology, Good Hope Hospital, University Hospitals Birmingham NHS Foundation Trust, Sutton Coldfield, U.K
| | - Shafie Kamaruddin
- Department of Diabetes and Endocrinology, County Durham and Darlington Foundation Trust, Darlington, U.K
| | - Eleanor Gurnell
- Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Trust, Cambridge, U.K
| | - Alyson Chapman
- Manchester University NHS Foundation Trust, Manchester Royal Infirmary, Manchester, U.K
| | - Sufyan Hussain
- Department of Diabetes, School of Cardiovascular, Metabolic Medicine and Sciences, King’s College London, London, U.K
- Department of Diabetes and Endocrinology, Guy’s and St. Thomas’ NHS Foundation Trust, London, U.K
| | - Jackie Elliott
- Diabetes and Endocrine Center, Sheffield Teaching Hospitals, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, U.K
| | - Lalantha Leelarathna
- Manchester University NHS Foundation Trust, Manchester Royal Infirmary, Manchester, U.K
| | - Robert E.J. Ryder
- Department of Diabetes and Endocrinology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, U.K
| | - Peter Hammond
- Department of Diabetes and Endocrinology, Harrogate and District NHS Trust, Harrogate, U.K
| | - Alistair Lumb
- Oxford Center for Diabetes Endocrinology and Metabolism, Oxford University Hospitals NHS Trust, Oxford, U.K
- National Institute for Health and Care Research, Oxford Biomedical Research Center, Oxford, U.K
| | - Pratik Choudhary
- Leicester Diabetes Center, University Hospitals of Leicester, Leicester, U.K
- Diabetes Research Center, College of Health Sciences, University of Leicester, Leicester, U.K
| | - Emma G. Wilmot
- Department of Diabetes and Endocrinology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trusts, Derby, U.K
- School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, U.K
| |
Collapse
|
3
|
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RKC, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol 2023; 34:251-261. [PMID: 36535566 DOI: 10.1016/j.annonc.2022.12.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 11/22/2022] [Accepted: 12/12/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, programmed death ligand 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted to further evaluate pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent and/or metastatic NPC. Final analysis results are presented. PATIENTS AND METHODS KEYNOTE-122 was an open-label, randomized study conducted at 29 sites, globally. Participants with platinum-pretreated recurrent and/or metastatic NPC were randomly assigned (1 : 1) to pembrolizumab or chemotherapy with capecitabine, gemcitabine, or docetaxel. Randomization was stratified by liver metastasis (present versus absent). The primary endpoint was overall survival (OS), analyzed in the intention-to-treat population using the stratified log-rank test (superiority threshold, one-sided P = 0.0187). Safety was assessed in the as-treated population. RESULTS Between 5 May 2016 and 28 May 2018, 233 participants were randomly assigned to treatment (pembrolizumab, n = 117; chemotherapy, n = 116); Most participants (86.7%) received study treatment in the second-line or later setting. Median time from randomization to data cut-off (30 November 2020) was 45.1 months (interquartile range, 39.0-48.8 months). Median OS was 17.2 months [95% confidence interval (CI) 11.7-22.9 months] with pembrolizumab and 15.3 months (95% CI 10.9-18.1 months) with chemotherapy [hazard ratio, 0.90 (95% CI 0.67-1.19; P = 0.2262)]. Grade 3-5 treatment-related adverse events occurred in 12 of 116 participants (10.3%) with pembrolizumab and 49 of 112 participants (43.8%) with chemotherapy. Three treatment-related deaths occurred: 1 participant (0.9%) with pembrolizumab (pneumonitis) and 2 (1.8%) with chemotherapy (pneumonia, intracranial hemorrhage). CONCLUSION Pembrolizumab did not significantly improve OS compared with chemotherapy in participants with platinum-pretreated recurrent and/or metastatic NPC but did have manageable safety and a lower incidence of treatment-related adverse events.
Collapse
Affiliation(s)
- A T C Chan
- State Key Laboratory in Translational Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, China.
| | - V H F Lee
- Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China
| | - R-L Hong
- National Taiwan University Hospital, Taipei, Taiwan
| | - M-J Ahn
- Samsung Medical Centre, Seoul, South Korea
| | - W Q Chong
- National University Cancer Institute, Singapore, Singapore
| | - S-B Kim
- Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
| | - G F Ho
- Clinical Oncology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
| | - P B Caguioa
- St. Luke's Medical Center, University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines
| | - N Ngamphaiboon
- Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - C Ho
- BC Cancer, University of British Columbia, Vancouver, Canada
| | - M A S A Aziz
- Gleneagles Penang Clinical Research Center, Gleneagles Hospital Penang, Penang, Malaysia
| | - Q S Ng
- National Cancer Centre Singapore, Singapore, Singapore
| | - C-J Yen
- National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | | | - R K-C Ngan
- Queen Elizabeth Hospital, Kowloon, Hong Kong, China
| | - S K Kho
- Hospital Umum Sarawak, Kuching, Malaysia
| | - M L A Tiambeng
- Cardinal Santos Medical Center, San Juan City, Philippines
| | - T Yun
- National Cancer Center, Goyang-si, South Korea
| | - V Sriuranpong
- Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| | | | - A Cheng
- Princess Margaret Hospital, Hong Kong, China
| | - E Massarelli
- City of Hope Comprehensive Cancer Center, Duarte, USA
| | | | - S Saraf
- Merck & Co., Inc., Rahway, USA
| | - J Yuan
- Merck & Co., Inc., Rahway, USA
| | - L L Siu
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| |
Collapse
|
4
|
Govind S, Jena A, Kamilla SK, Mohanty N, Mallikarjuna RM, Nalawade T, Saraf S, Khaldi NA, Jahdhami SA, Shivagange V. Diagnosis and Assessment of Dental Caries Using Novel Bioactive Caries Detecting Dye Solution. Biomedicines 2023; 11:biomedicines11020500. [PMID: 36831036 PMCID: PMC9953294 DOI: 10.3390/biomedicines11020500] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 01/26/2023] [Accepted: 01/29/2023] [Indexed: 02/11/2023] Open
Abstract
BACKGROUND The goal of materials should be early caries detection, removal of carious lesions, and reduction of dentin hypersensitivity. Thus, the study aims to determine the efficacy of a bioactive caries detecting dye (BCD) for the diagnosing and mechanical removal of occlusal and proximal dental caries. METHODS Patients with occlusal (A1, A2) and proximal carious lesions (B1, B2) were treated with the rotary technique and BCD solution on 120 teeth (n = 60 for each). Group 1: Excavation was performed using diamond points. Group 2: 0.5 mL of BCD solution was scrubbed for 20 sec and excavation was performed with a sharp spoon excavator. Post-excavation cavity volume analysis was performed using a 3D scanner. The time required, VAS for pain, VAS for facial expression, and sound eye motor scoring were scored during excavation. Post-restoration evaluation was performed at 3, 6, and 12 months (FDI criteria). RESULTS The chi-square test revealed that the A1 (197.90 30.97 s) and B1 (273.06 69.95 s) had significantly less mean procedural time than the A2 (292.13 44.87 s) and B2 (411.86 88.34 s). BCD (A2, B2) group showed good patient acceptance, less pain during caries excavation VAS (p = 0.001, FACE (p = 0.001), and SEM (p < 0.001) analysis than the rotary group. There was a statistically insignificant difference between groups immediately (p = 0.235), (p = 0.475) and after 24 h (p = 0.561), (p = 0.688). Color score, hardness of excavated surface, and caries removal score for occlusal and proximal groups showed insignificant differences between the groups. BCD group showed significantly less mean caries excavated volume for the occlusal group (p = 0.003) as compared to the proximal group (p = 0.417) evaluated by 3D scanner. Evaluation of restoration after 3-, 6-, and 12 months intervals (Occlusal caries group (p = 0.247), (p = 0.330), and (0.489) and Proximal caries group (p = 0.299), (p = 0.594), and (0.494)) was acceptable for both the groups. CONCLUSION BCD helps in identification of dental caries clinically, radiographically, and in effective removal of denatured teeth with less pain or sensitivity.
Collapse
Affiliation(s)
- Shashirekha Govind
- Department of Conservative Dentistry and Endodontics, Institute of Dental Sciences, Siksha ‘O’ Anusandhan (Deemed to be) University, Bhubaneswar 751003, India
- Correspondence: ; Tel.: +91-933-845-7955
| | - Amit Jena
- Department of Conservative Dentistry and Endodontics, Sriram Chandra Bhanja Dental College & Hospital, Cuttack 753007, India
| | - Sushanta Kumar Kamilla
- Department of Physics, Institute of Technical Education and Research, Siksha ‘O’ Anusandhan (Deemed to be) University, Bhubaneswar 751003, India
| | - Neeta Mohanty
- Department of Oral Pathology and Microbiology, Institute of Dental Sciences, Siksha ‘O’Anusandhan (Deemed to be) University, Bhubaneswar 751003, India
| | - Rachappa M. Mallikarjuna
- Department of Paediatric Dentistry, Child Dental Health, Oman Dental College, Mina Al Fahal, Muscat, Wattayah 116, Oman
| | - Triveni Nalawade
- Department of Paediatric Dentistry, Child Dental Health, Oman Dental College, Mina Al Fahal, Muscat, Wattayah 116, Oman
| | - Sanjay Saraf
- Department of Oral Biology and Oral Pathology, Oman Dental College, Mina Al Fahal, Muscat, Wattayah 116, Oman
| | - Naseer Al Khaldi
- Consultant Prosthodontist, Al-Nahdha Hospital, Al Khuwair, Muscat 133, Oman
| | - Salma Al Jahdhami
- Specialist, Oral and Maxillofacial Surgeon, Al-Nahdha Hospital, Al Khuwair, Muscat 133, Oman
| | - Vinay Shivagange
- Department of Conservative Dentistry and Endodontics, Saveetha Dental College, Chennai 600077, India
| |
Collapse
|
5
|
Rengarajan LN, Nash K, Ooi E, Cooper C, Birchenough A, Owen M, Saraf S, Karamat A, De P, Krishnasamy S, Narendran P, Kempegowda P. Sustaining improvement in diabetes-related ketoacidosis management through a Quality Improvement ProjectSustaining improvement in diabetic ketoacidosis management through Quality Improvement Project. Br J Diabetes 2022. [DOI: 10.15277/bjd.2022.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
6
|
Skaria M, Ponniah G, Birchenough A, Owen M, Pan C, Soghal S, Warmington E, Sheikh H, Karamat A, Saraf S, Kempegowda P. Trends in rates of complications and adverse outcomes in diabetic ketoacidosis following changes to the Joint British Diabetes Societies' management guidelines. Clin Med (Lond) 2022; 22 Suppl 4:71. [PMID: 38614603 PMCID: PMC9600808 DOI: 10.7861/clinmed.22-4-s71] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
| | | | - Amy Birchenough
- Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
| | | | - Carina Pan
- University of Birmingham, Birmingham, UK
| | | | | | | | | | | | | |
Collapse
|
7
|
Halmos B, Cobb P, Johnson M, Jain L, Kim S, Saraf S, Lala M, Kurata T. 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Chan A, Lee H, Hong RL, Ahn MJ, Chong W, Kim SB, Fuang H, Caguioa P, Ngamphaiboon N, Ho C, Abdul Aziz M, Ng Q, Yen C, Soparattanapaisarn N, Ngan R, Kho S, Wang L, Swaby R, Saraf S, Siu L. 163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Chan A, Lee V, Hong RL, Ahn MJ, Chong W, Kim SB, Gwo Fuang H, Caguioa P, Ngamphaiboon N, Ho C, Abdul Aziz M, Ng Q, Yen CJ, Soparattanapaisarn N, Ngan K, Kho S, Swaby R, Saraf S, Ge J, Siu L. 858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1268] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
10
|
Awad M, Gadgeel S, Borghaei H, Patnaik A, Chih-Hsin Yang J, Powell S, Gentzler R, Martins R, Stevenson J, Altan M, Jalal S, Panwalkar A, Gubens M, Sequist L, Saraf S, Zhao B, Piperdi B, Langer C. OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Al Ismaili A, Al Busaidi K, Nalawade T, Saraf S. Immune-mediated Skin Disorders and their Oral Manifestations in the Omani Population: A Hospital-based Study. Oman Med J 2020; 35:e84. [PMID: 32042465 PMCID: PMC6976739 DOI: 10.5001/omj.2020.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 03/25/2019] [Indexed: 01/01/2023] Open
Abstract
Objectives We sought to determine the prevalence of immune-mediated skin disorders (IMDs), their oral manifestations, and the related comorbidity among Omani patients with IMDs attending the outpatient Department of Dermatology and Dental Clinic at Al Nahdha Hospital, Muscat. Methods We conducted a retrospective study of 236 newly-diagnosed patients with IMDs who attended the outpatient clinic between September 2014 and September 2017. Data, such as age, sex, investigations, diagnosis, comorbidity, and associated oral manifestations of the affected individuals, were collected from the hospital health information system. Results Of the 236 diagnosed cases of IMD, lichen planus substantially comprised over half of the total cases (59.7%). This was followed by relatively fewer cases of discoid lupus erythematosus (11.0%), systemic lupus erythematosus (10.2%), and erythema multiforme (8.1%). Pemphigus vulgaris and bullous pemphigus comprised only 3.0% and 4.2% of the total studied cases, respectively. The other less common disorders found in our study were toxic epidermal necrolysis (1.7%), pemphigus foliaceus (1.3%), and gestational pemphigoid (0.8%). Oral mucosal involvement was seen more commonly with lichen planus (78.7%), pemphigus vulgaris (71.4%), and erythema multiforme (75.0%), while systemic lupus erythematosus and discoid lupus erythematosus were shown to appear with more comorbidities compared to the other skin disorders studied. Conclusions Several IMDs have considerable oral involvement. These oral manifestations of the diseases may be overlooked by other specialists leading to a delay in the diagnosis and its management. In order to circumvent this delay, the analysis and evaluation of a disease need to be done by a team comprising of a dental surgeon, dermatologist, and an oral medicine specialist.
Collapse
Affiliation(s)
| | - Khalid Al Busaidi
- Dermatology Residency Program, Oman Medical Specialty Board, Muscat, Oman
| | - Triveni Nalawade
- Department of Pediatric Dentistry, Oman Dental College, Muscat, Oman
| | - Sanjay Saraf
- Oral Basic Sciences, Oman Dental College, Muscat, Oman
| |
Collapse
|
12
|
Koshy M, Son C, Spiotto M, Rondelli D, Saraf S. Prospective Evaluation of Total Body Radiation in the Conditioning Regimen of Patients Undergoing Allogeneic Stem Cell Transplantation for Sickle Cell Disease. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Saraf S. Tourniquet-induced purpura during hand surgery. J Orthop Traumatol Rehabil 2019. [DOI: 10.4103/jotr.jotr_47_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
14
|
Borghaei H, Langer C, Gadgeel S, Papadimitrakopoulou V, Patnaik A, Powell S, Gentzler R, Martins R, Stevenson J, Jalal S, Panwalkar A, Yang JH, Gubens M, Sequist L, Awad M, Fiore J, Saraf S, Raftopoulos H, Gandhi L. Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.052] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Ahmad M, Brient CE, Egun PM, Grimes SM, Saraf S, Satyanarayana H. Charged-Particle Emission in Reactions of 9- and 11 -MeV Neutrons with63,65Cu. NUCL SCI ENG 2017. [DOI: 10.13182/nse95-296] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Munir Ahmad
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2A3
| | - C. E. Brient
- John E. Edwards Accelerator Laboratory, Ohio University, Athens, Ohio 45701
| | - P. M. Egun
- John E. Edwards Accelerator Laboratory, Ohio University, Athens, Ohio 45701
| | - S. M. Grimes
- John E. Edwards Accelerator Laboratory, Ohio University, Athens, Ohio 45701
| | - S. Saraf
- John E. Edwards Accelerator Laboratory, Ohio University, Athens, Ohio 45701
| | - H. Satyanarayana
- John E. Edwards Accelerator Laboratory, Ohio University, Athens, Ohio 45701
| |
Collapse
|
16
|
Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017; 28:1036-1041. [PMID: 28453692 PMCID: PMC5406758 DOI: 10.1093/annonc/mdx029] [Citation(s) in RCA: 171] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for patients with programmed death ligand 1 (PD-L1)-positive advanced solid tumors. We report results for the cohort of patients with advanced anal carcinoma. Patients and methods Patients with PD-L1-positive tumors (≥1%) received intravenous pembrolizumab 10 mg/kg once every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter per Response Evaluation Criteria In Solid Tumors, version 1.1. Primary endpoints were safety and overall response rate per investigator review. Secondary endpoints included progression-free survival, overall survival, and response duration. Data cutoff date was 1 July 2015. Results Of the 43 patients with advanced anal carcinoma evaluable for PD-L1 expression, 32 (74%) had PD-L1-positive tumors as assessed with the 22C3 prototype assay, of whom 25 were enrolled between April and September 2014. Sixteen patients (64%) experienced treatment-related adverse events; the most common ones were diarrhea and fatigue in four patients (16%) each and nausea in three patients (12%). There were no treatment-related deaths or discontinuations as of the data cutoff date. Among the 24 patients with squamous cell carcinoma histology, four had confirmed partial response, for an overall response rate of 17% [95% confidence interval (CI), 5%-37%) and 10 (42%) had confirmed stable disease, for a disease control rate of 58%. One additional patient with non-squamous histology had confirmed stable disease. Conclusion In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity. These data support further study of pembrolizumab for this patient population. ClinicalTrials.gov NCT02054806.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Anal Canal/pathology
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antineoplastic Agents, Immunological/adverse effects
- Antineoplastic Agents, Immunological/therapeutic use
- Anus Neoplasms/drug therapy
- Anus Neoplasms/mortality
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/mortality
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/mortality
- Treatment Outcome
Collapse
Affiliation(s)
- P. A. Ott
- Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston
| | - S. A. Piha-Paul
- Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
| | - P. Munster
- Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
| | - M. J. Pishvaian
- Department of Hematology/Oncology, Georgetown University, Washington DC, USA
| | - E. M. J. van Brummelen
- Department of Molecular Pathology & Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - R. B. Cohen
- Department of Medicine, University of Pennsylvania, Philadelphia, USA
| | - C. Gomez-Roca
- Clinical Research Unit, Institut Claudius Regaud and Institut Universitaire du Cancer—Oncopole, Toulouse, France
| | - S. Ejadi
- Department of Medical Oncology, Virginia G. Piper Cancer Center, Scottsdale
| | - M. Stein
- Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick
| | - E. Chan
- Department of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - M. Simonelli
- Department of Medical Oncology and Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - A. Morosky
- Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA
| | - S. Saraf
- Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA
| | - K. Emancipator
- Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA
| | - M. Koshiji
- Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA
| | - J. Bennouna
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Nantes, France
| |
Collapse
|
17
|
Chan A, Lee V, Ngan R, To K, Ahn MJ, Ng Q, Hong RL, Lin JC, Swaby R, Gause C, Saraf S, Spreafico A. 394TiP KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw587.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Hansen A, Massard C, Ott P, Haas N, Lopez J, Ejadi S, Wallmark J, Keam B, Delord JP, Aggarwal R, Gould M, Qiu P, Saraf S, Keefe S, Piha-Paul S. Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.09] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Hsu C, Lee SH, Ejadi S, Even C, Cohen R, Le Tourneau C, Mehnert J, Algazi A, van Brummelen E, Saraf S, Thanigaimani P, Cheng J, Hansen A. 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv527.02] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Saraf S, Shandra S, Saran R, Narain V, Dwivedi S, Sethi R, Pradhan A, Chaudhary G, Vishwakarma P. To detect occult coronary artery disease in global severe left ventricular hypokinesia. Indian Heart J 2015. [DOI: 10.1016/j.ihj.2015.10.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
21
|
Shipman KE, Sinha C, Saraf S, Milles JJ, Moloney M, Ramachandran S. Paradoxical glycaemic response to surgical treatment of ovarian hyperthecosis in a patient with type 2 diabetes. Br J Diabetes 2015. [DOI: 10.15277/bjdvd.2014.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
22
|
Raveendran S, Kyprianou K, Zenonos K, Saraf S. A patient presenting with collapse and breathlessness. Acute Med 2015; 14:176-194. [PMID: 27119131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
23
|
Prabakar C, Irani M, Julka N, Bhatt D, Homel P, Saraf S, Bral P. What Your Patient Does Not Know: A Survey of Patient Knowledge about Surgical Approaches in Gynecology. J Minim Invasive Gynecol 2014. [DOI: 10.1016/j.jmig.2014.08.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Sherwin G, Akpinar P, Saraf S, Li X. Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets. Value Health 2014; 17:A785. [PMID: 27202919 DOI: 10.1016/j.jval.2014.08.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- G Sherwin
- ICON Pricing and Market Access, London, UK
| | - P Akpinar
- ICON Pricing and Market Access, London, UK
| | - S Saraf
- ICON Pricing and Market Access, London, UK
| | - X Li
- ICON Commercialisation & Outcomes, London, UK
| |
Collapse
|
25
|
Akpinar P, Saraf S, Severi Bruni D, Li X, Liu C, Sherwin G. Stakeholder Evidence Requirements and Price Expectations for Biosimilars in Three Asian Markets. Value Health 2014; 17:A775. [PMID: 27202867 DOI: 10.1016/j.jval.2014.08.339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Affiliation(s)
- P Akpinar
- ICON Pricing and Market Access, London, UK
| | - S Saraf
- ICON Pricing and Market Access, London, UK
| | | | - X Li
- ICON Commercialisation & Outcomes, London, UK
| | - C Liu
- ICON Pricing and Market Access, New York, NY, USA
| | - G Sherwin
- ICON Pricing and Market Access, London, UK
| |
Collapse
|
26
|
Akpinar P, Saraf S, Severi Bruni D, Li X, Liu C, Sherwin G. Stakeholder Evidence Requirements and Price Expectations for Biosimilars in Three Asian Markets. Value Health 2014; 17:A775-A776. [PMID: 27202867 DOI: 10.1016/j.jval.2014.08.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- P Akpinar
- ICON Pricing and Market Access, London, UK
| | - S Saraf
- ICON Pricing and Market Access, London, UK
| | | | - X Li
- ICON Commercialisation & Outcomes, London, UK
| | - C Liu
- ICON Pricing and Market Access, New York, NY, USA
| | - G Sherwin
- ICON Pricing and Market Access, London, UK
| |
Collapse
|
27
|
Sherwin G, Saraf S, Li X, Akpinar P. Provincial Hospital Tendering in China: Evaluating The Impact on Price. Value Health 2014; 17:A788. [PMID: 27202938 DOI: 10.1016/j.jval.2014.08.419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- G Sherwin
- ICON Pricing and Market Access, London, UK
| | - S Saraf
- ICON Pricing and Market Access, London, UK
| | - X Li
- ICON Commercialisation & Outcomes, London, UK
| | - P Akpinar
- ICON Pricing and Market Access, London, UK
| |
Collapse
|
28
|
Eaton KA, Suvan JE, Saraf S, Rist A. Introducing dental hygienists in general practice to research - an in-practice evaluation programme in the United Kingdom. Int J Dent Hyg 2014; 13:228-34. [PMID: 25318647 DOI: 10.1111/idh.12108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2014] [Indexed: 11/28/2022]
Abstract
AIM To introduce dental hygienists (DHs) in the UK to the principles of research through a practice-based product evaluation programme. METHODS The programme consisted of an initial training and orientation day with presentations on evidence-based practice, research methods and the structure of research papers. The programme and its aims were explained in detail, and participants were briefed on the methods to be used. Participants then recruited seven to ten patients from their practices (offices), carried out a baseline assessment of: plaque, gingival health, calculus and staining at anterior teeth, and gave the patients a questionnaire asking about their teeth and then provided a 3-month supply of a test toothpaste. About 10 weeks later, a follow-up assessment of the same variables was performed and the questionnaire was repeated. A second training day followed during which the DHs provided feedback of their experiences and received training in literature searching and critical appraisal of literature including interpretation of results. RESULTS Sixty-five DHs attended the first training day; 31 were able to recruit sufficient patients and attend the second training day. The DHs recruited 168 patients who received baseline and follow-up assessments. All the variables improved overall. Feedback from the DHs was very positive, and patients expressed delight with the care they had received. CONCLUSIONS Qualitative feedback for participating DHs suggests the programme met its aim and could be used in the future as a mechanism for helping DHs who want to increase their understanding of research methodology.
Collapse
Affiliation(s)
- K A Eaton
- Eastman and King's College London Dental Institutes, University College London, UK.,University of Kent, Ashford, UK
| | - J E Suvan
- Eastman Clinical Investigation Centre, University College London, London, UK
| | - S Saraf
- Oral-B, Procter & Gamble Western Europe, Geneva, Switzerland
| | - A Rist
- Oral-B, Procter & Gamble Western Europe, Geneva, Switzerland
| |
Collapse
|
29
|
Wagner J, Saraf S, Fridman D. A Simplified Standardized Technique for LESS (Laparoendoscopic Single Site Surgery) Hysterectomy: Experience with over 300 Cases. J Minim Invasive Gynecol 2013. [DOI: 10.1016/j.jmig.2013.08.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Abstract
An unusual case of palmar implantation dermoid causing paresthesia in the fingers is reported. The tumor was successfully excised with relief of the symptoms. The report discusses important points regarding management of such tumors.
Collapse
Affiliation(s)
- Sanjay Saraf
- Department of Plastic Surgery, NMC Specialty Hospital, Dubai, UAE
| |
Collapse
|
31
|
Affiliation(s)
- Sanjay Saraf
- Department of Plastic Surgery, NMC Specialty Hospital, Dubai, UAE
| |
Collapse
|
32
|
Abadie J, Abbott BP, Abbott R, Adhikari R, Ajith P, Allen B, Allen G, Amador Ceron E, Amin RS, Anderson SB, Anderson WG, Arain MA, Araya M, Aso Y, Aston S, Aufmuth P, Aulbert C, Babak S, Baker P, Ballmer S, Barker D, Barr B, Barriga P, Barsotti L, Barton MA, Bartos I, Bassiri R, Bastarrika M, Behnke B, Benacquista M, Bennett MF, Betzwieser J, Beyersdorf PT, Bilenko IA, Billingsley G, Biswas R, Black E, Blackburn JK, Blackburn L, Blair D, Bland B, Bock O, Bodiya TP, Bondarescu R, Bork R, Born M, Bose S, Brady PR, Braginsky VB, Brau JE, Breyer J, Bridges DO, Brinkmann M, Britzger M, Brooks AF, Brown DA, Bullington A, Buonanno A, Burmeister O, Byer RL, Cadonati L, Cain J, Camp JB, Cannizzo J, Cannon KC, Cao J, Capano C, Cardenas L, Caudill S, Cavaglià M, Cepeda C, Chalermsongsak T, Chalkley E, Charlton P, Chatterji S, Chelkowski S, Chen Y, Christensen N, Chua SSY, Chung CTY, Clark D, Clark J, Clayton JH, Conte R, Cook D, Corbitt TRC, Cornish N, Coward D, Coyne DC, Creighton JDE, Creighton TD, Cruise AM, Culter RM, Cumming A, Cunningham L, Dahl K, Danilishin SL, Danzmann K, Daudert B, Davies G, Daw EJ, Dayanga T, DeBra D, Degallaix J, Dergachev V, DeSalvo R, Dhurandhar S, Díaz M, Donovan F, Dooley KL, Doomes EE, Drever RWP, Driggers J, Dueck J, Duke I, Dumas JC, Dwyer S, Edgar M, Edwards M, Effler A, Ehrens P, Etzel T, Evans M, Evans T, Fairhurst S, Faltas Y, Fan Y, Fazi D, Fehrmann H, Finn LS, Flasch K, Foley S, Forrest C, Fotopoulos N, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Friedrich D, Fritschel P, Frolov VV, Fulda P, Fyffe M, Garofoli JA, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Goetz E, Goggin LM, González G, Goßler S, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Grosso R, Grote H, Grunewald S, Gustafson EK, Gustafson R, Hage B, Hallam JM, Hammer D, Hammond GD, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Haughian K, Hayama K, Hayler T, Heefner J, Heng IS, Heptonstall A, Hewitson M, Hild S, Hirose E, Hoak D, Hodge KA, Holt K, Hosken DJ, Hough J, Howell E, Hoyland D, Hughey B, Husa S, Huttner SH, Ingram DR, Isogai T, Ivanov A, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kandhasamy S, Kanner J, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khan R, Khazanov E, Kim H, King PJ, Kissel JS, Klimenko S, Kokeyama K, Kondrashov V, Kopparapu R, Koranda S, Kozak D, Kringel V, Krishnan B, Kuehn G, Kullman J, Kumar R, Kwee P, Lam PK, Landry M, Lang M, Lantz B, Lastzka N, Lazzarini A, Leaci P, Lei M, Leindecker N, Leonor I, Lin H, Lindquist PE, Littenberg TB, Lockerbie NA, Lodhia D, Lormand M, Lu P, Lubinski M, Lucianetti A, Lück H, Lundgren A, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Mak C, Mandel I, Mandic V, Márka S, Márka Z, Markosyan A, Markowitz J, Maros E, Martin IW, Martin RM, Marx JN, Mason K, Matichard F, Matone L, Matzner RA, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McKechan DJA, Mehmet M, Melatos A, Melissinos AC, Mendell G, Menéndez DF, Mercer RA, Merrill L, Meshkov S, Messenger C, Meyer MS, Miao H, Miller J, Mino Y, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Moe B, Mohanty SD, Mohapatra SRP, Moreno G, Mors K, Mossavi K, MowLowry C, Mueller G, Müller-Ebhardt H, Mukherjee S, Mullavey A, Munch J, Murray PG, Nash T, Nawrodt R, Nelson J, Newton G, Nishida E, Nishizawa A, O’Dell J, O’Reilly B, O’Shaughnessy R, Ochsner E, Ogin GH, Oldenburg R, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Page A, Pan Y, Pankow C, Papa MA, Patel P, Pathak D, Pedraza M, Pekowsky L, Penn S, Peralta C, Perreca A, Pickenpack M, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Postiglione F, Principe M, Prix R, Prokhorov L, Puncken O, Quetschke V, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raics Z, Rakhmanov M, Raymond V, Reed CM, Reed T, Rehbein H, Reid S, Reitze DH, Riesen R, Riles K, Roberts P, Robertson NA, Robinson C, Robinson EL, Roddy S, Röver C, Rollins J, Romano JD, Romie JH, Rowan S, Rüdiger A, Ryan K, Sakata S, Sammut L, Sancho de la Jordana L, Sandberg V, Sannibale V, Santamaría L, Santostasi G, Saraf S, Sarin P, Sathyaprakash BS, Sato S, Satterthwaite M, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield R, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Searle AC, Seifert F, Sellers D, Sengupta AS, Sergeev A, Shapiro B, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Sintes AM, Skelton G, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Speirits F, Stein AJ, Stein LC, Steplewski S, Stochino A, Stone R, Strain KA, Strigin S, Stroeer A, Stuver AL, Summerscales TZ, Sung M, Susmithan S, Sutton PJ, Szokoly GP, Talukder D, Tanner DB, Tarabrin SP, Taylor JR, Taylor R, Thorne KA, Thorne KS, Thüring A, Titsler C, Tokmakov KV, Torres C, Torrie CI, Traylor G, Trias M, Turner L, Ugolini D, Urbanek K, Vahlbruch H, Vallisneri M, Van Den Broeck C, van der Sluys MV, van Veggel AA, Vass S, Vaulin R, Vecchio A, Veitch J, Veitch PJ, Veltkamp C, Villar A, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Wanner A, Ward RL, Wei P, Weinert M, Weinstein AJ, Weiss R, Wen L, Wen S, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Wilkinson C, Willems PA, Williams HR, Williams L, Willke B, Wilmut I, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Yakushin I, Yamamoto H, Yamamoto K, Yeaton-Massey D, Yoshida S, Zanolin M, Zhang L, Zhang Z, Zhao C, Zotov N, Zucker ME, Zweizig J, Buchner S. Publisher’s Note: Search for gravitational waves associated with the August 2006 timing glitch of the Vela pulsar [Phys. Rev. D83, 042001 (2011)]. Int J Clin Exp Med 2012. [DOI: 10.1103/physrevd.85.089902] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
33
|
Abadie J, Abbott BP, Abbott R, Abernathy M, Accadia T, Acernese F, Adams C, Adhikari R, Ajith P, Allen B, Allen G, Amador Ceron E, Amin RS, Anderson SB, Anderson WG, Antonucci F, Arain MA, Araya M, Aronsson M, Arun KG, Aso Y, Aston S, Astone P, Atkinson DE, Aufmuth P, Aulbert C, Babak S, Baker P, Ballardin G, Ballinger T, Ballmer S, Barker D, Barnum S, Barone F, Barr B, Barriga P, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Bastarrika M, Bauchrowitz J, Bauer TS, Behnke B, Beker MG, Belletoile A, Benacquista M, Bertolini A, Betzwieser J, Beveridge N, Beyersdorf PT, Bigotta S, Bilenko IA, Billingsley G, Birch J, Birindelli S, Biswas R, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bland B, Blom M, Boccara C, Bock O, Bodiya TP, Bondarescu R, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Bose S, Bosi L, Bouhou B, Boyle M, Braccini S, Bradaschia C, Brady PR, Braginsky VB, Brau JE, Breyer J, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Budzyński R, Bulik T, Bulten HJ, Buonanno A, Burguet-Castell J, Burmeister O, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Cain J, Calloni E, Camp JB, Campagna E, Campsie P, Cannizzo J, Cannon KC, Canuel B, Cao J, Capano C, Carbognani F, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cesarini E, Chalermsongsak T, Chalkley E, Charlton P, Chassande-Mottin E, Chelkowski S, Chen Y, Chincarini A, Christensen N, Chua SSY, Chung CTY, Clark D, Clark J, Clayton JH, Cleva F, Coccia E, Colacino CN, Colas J, Colla A, Colombini M, Conte R, Cook D, Corbitt TR, Cornish N, Corsi A, Costa CA, Coulon JP, Coward D, Coyne DC, Creighton JDE, Creighton TD, Cruise AM, Culter RM, Cumming A, Cunningham L, Cuoco E, Dahl K, Danilishin SL, Dannenberg R, D’Antonio S, Danzmann K, Das K, Dattilo V, Daudert B, Davier M, Davies G, Davis A, Daw EJ, Day R, Dayanga T, De Rosa R, DeBra D, Degallaix J, del Prete M, Dergachev V, DeRosa R, DeSalvo R, Devanka P, Dhurandhar S, Di Fiore L, Di Lieto A, Di Palma I, Di Paolo Emilio M, Di Virgilio A, Díaz M, Dietz A, Donovan F, Dooley KL, Doomes EE, Dorsher S, Douglas ESD, Drago M, Drever RWP, Driggers JC, Dueck J, Dumas JC, Dwyer S, Eberle T, Edgar M, Edwards M, Effler A, Ehrens P, Ely G, Engel R, Etzel T, Evans M, Evans T, Fafone V, Fairhurst S, Fan Y, Farr BF, Fazi D, Fehrmann H, Feldbaum D, Ferrante I, Fidecaro F, Finn LS, Fiori I, Flaminio R, Flanigan M, Flasch K, Foley S, Forrest C, Forsi E, Fotopoulos N, Fournier JD, Franc J, Frasca S, Frasconi F, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Friedrich D, Fritschel P, Frolov VV, Fulda P, Fyffe M, Galimberti M, Gammaitoni L, Garofoli JA, Garufi F, Gemme G, Genin E, Gennai A, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Giazotto A, Gill C, Goetz E, Goggin LM, González G, Goßler S, Gouaty R, Graef C, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Greverie C, Grosso R, Grote H, Grunewald S, Guidi GM, Gustafson EK, Gustafson R, Hage B, Hall P, Hallam JM, Hammer D, Hammond G, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Haughian K, Hayama K, Hayau JF, Hayler T, Heefner J, Heitmann H, Hello P, Heng IS, Heptonstall A, Hewitson M, Hild S, Hirose E, Hoak D, Hodge KA, Holt K, Hosken DJ, Hough J, Howell E, Hoyland D, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Ingram DR, Inta R, Isogai T, Ivanov A, Jaranowski P, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kandhasamy S, Kanner J, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim H, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kondrashov V, Kopparapu R, Koranda S, Kowalska I, Kozak D, Krause T, Kringel V, Krishnamurthy S, Krishnan B, Królak A, Kuehn G, Kullman J, Kumar R, Kwee P, Landry M, Lang M, Lantz B, Lastzka N, Lazzarini A, Leaci P, Leong J, Leonor I, Leroy N, Letendre N, Li J, Li TGF, Lin H, Lindquist PE, Lockerbie NA, Lodhia D, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lu P, Luan J, Lubinski M, Lucianetti A, Lück H, Lundgren A, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Majorana E, Mak C, Maksimovic I, Man N, Mandel I, Mandic V, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Marx JN, Mason K, Masserot A, Matichard F, Matone L, Matzner RA, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIvor G, McKechan DJA, Meadors G, Mehmet M, Meier T, Melatos A, Melissinos AC, Mendell G, Menéndez DF, Mercer RA, Merill L, Meshkov S, Messenger C, Meyer MS, Miao H, Michel C, Milano L, Miller J, Minenkov Y, Mino Y, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Mohan M, Mohanty SD, Mohapatra SRP, Moraru D, Moreau J, Moreno G, Morgado N, Morgia A, Mors K, Mosca S, Moscatelli V, Mossavi K, Mours B, MowLowry C, Mueller G, Mukherjee S, Mullavey A, Müller-Ebhardt H, Munch J, Murray PG, Nash T, Nawrodt R, Nelson J, Neri I, Newton G, Nishida E, Nishizawa A, Nocera F, Nolting D, Ochsner E, O’Dell J, Ogin GH, Oldenburg RG, O’Reilly B, O’Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Page A, Pagliaroli G, Palladino L, Palomba C, Pan Y, Pankow C, Paoletti F, Papa MA, Pardi S, Pareja M, Parisi M, Pasqualetti A, Passaquieti R, Passuello D, Patel P, Pathak D, Pedraza M, Pekowsky L, Penn S, Peralta C, Perreca A, Persichetti G, Pichot M, Pickenpack M, Piergiovanni F, Pietka M, Pinard L, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Poggiani R, Postiglione F, Prato M, Predoi V, Price LR, Prijatelj M, Principe M, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Quetschke V, Raab FJ, Rabeling DS, Radke T, Radkins H, Raffai P, Rakhmanov M, Rankins B, Rapagnani P, Raymond V, Re V, Reed CM, Reed T, Regimbau T, Reid S, Reitze DH, Ricci F, Riesen R, Riles K, Roberts P, Robertson NA, Robinet F, Robinson C, Robinson EL, Rocchi A, Roddy S, Röver C, Rolland L, Rollins J, Romano JD, Romano R, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sakata S, Sakosky M, Salemi F, Sammut L, Sancho de la Jordana L, Sandberg V, Sannibale V, Santamaría L, Santostasi G, Saraf S, Sassolas B, Sathyaprakash BS, Sato S, Satterthwaite M, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield R, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Searle AC, Seifert F, Sellers D, Sengupta AS, Sentenac D, Sergeev A, Shaddock D, Shapiro B, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Singer A, Sintes AM, Skelton G, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Speirits FC, Sperandio L, Stein AJ, Stein LC, Steinlechner S, Steplewski S, Stochino A, Stone R, Strain KA, Strigin S, Stroeer A, Sturani R, Stuver AL, Summerscales TZ, Sung M, Susmithan S, Sutton PJ, Swinkels B, Talukder D, Tanner DB, Tarabrin SP, Taylor JR, Taylor R, Thomas P, Thorne KA, Thorne KS, Thrane E, Thüring A, Titsler C, Tokmakov KV, Toncelli A, Tonelli M, Torre O, Torres C, Torrie CI, Tournefier E, Travasso F, Traylor G, Trias M, Trummer J, Tseng K, Turner L, Ugolini D, Urbanek K, Vahlbruch H, Vaishnav B, Vajente G, Vallisneri M, van den Brand JFJ, Van Den Broeck C, van der Putten S, van der Sluys MV, van Veggel AA, Vass S, Vaulin R, Vavoulidis M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Veltkamp C, Verkindt D, Vetrano F, Viceré A, Villar A, Vinet JY, Vocca H, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Wanner A, Ward RL, Was M, Wei P, Weinert M, Weinstein AJ, Weiss R, Wen L, Wen S, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, White DJ, Whiting BF, Wilkinson C, Willems PA, Williams L, Willke B, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Yakushin I, Yamamoto H, Yamamoto K, Yeaton-Massey D, Yoshida S, Yu PP, Yvert M, Zanolin M, Zhang L, Zhang Z, Zhao C, Zotov N, Zucker ME, Zweizig J. Publisher’s Note: Search for gravitational waves from compact binary coalescence in LIGO and Virgo data from S5 and VSR1 [Phys. Rev. D82, 102001 (2010)]. Int J Clin Exp Med 2012. [DOI: 10.1103/physrevd.85.089903] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
34
|
Abbas A, Saraf S, Ramachandran S, Raju J, Ramachandran S. Fibrates and estimated glomerular filtration rate: observations from an outpatient clinic setting and clinical implications. Postgrad Med J 2012; 88:503-6. [PMID: 22460858 DOI: 10.1136/postgradmedj-2011-130594] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Previous studies have demonstrated that fibrates have an effect on creatinine concentrations. The pattern of change with fibrates in estimated glomerular filtration rate (eGFR), widely used in clinical practice, has not been previously described. METHODS Data was retrospectively collected from 132 consecutive case notes of patients started on fibrates in a lipid clinic between 2002 and 2008. Pre- and post-fibrate creatinine concentrations were measured and eGFR measurements were obtained. RESULTS Of the 79 patients with both pre and post-treatment eGFR values <90 ml/min/1.73 m(2), a significant mean eGFR reduction of 8.2 ml/min/1.73 m(2) was noted. Of these patients, 50% demonstrated a reduction in eGFR >8 ml/min/1.73 m(2), 25% demonstrated a reduction >16 ml/min/1.73 m(2), and 10% demonstrated a reduction >21 ml/min/1.73 m(2). CONCLUSIONS The authors demonstrate a significant effect of fibrates on eGFR in clinical practice. Awareness of the pattern of eGFR change is important for decisions regarding the continued use of fibrate therapy and/or commonly co-prescribed diabetic drugs and renal specialist referrals.
Collapse
Affiliation(s)
- Ahmed Abbas
- Department of Clinical Biochemistry, Heart of England NHS Foundation Trust, Good Hope Hospital, Rectory Road, Sutton Coldfield, West Midlands B75 7RR, UK
| | | | | | | | | |
Collapse
|
35
|
Saraf S, Patel P, Ozer H, Peace D, Quigley J, Mahmud N, Rondelli D. Improved Outcome of African American Multiple Myeloma Patients with Novel Agents and Autologous Stem Cell Transplant. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
36
|
Ramachandran S, Abbas A, Saraf S, Raju J, Jewkes C, Jones AF. Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting. Metab Syndr Relat Disord 2012; 10:189-94. [PMID: 22283634 DOI: 10.1089/met.2011.0112] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Change in high-density lipoprotein cholesterol (HDL-C) observed in large randomized controlled trials using fibrates has varied. Inconsistent cardiovascular outcomes have also been the common theme of these trials. Subgroup analysis of even the negative trials, however, reveals significant reduction in cardiovascular disease in patients with low HDL-C and high triglycerides. We wished to study HDL-C change following fibrate therapy in our lipid clinic and determine the factors associated with HDL-C change. METHODS Data were collected from case notes of patients started on fibrates (n=248) between 2002 and 2008 in the lipid clinics at Heart of England NHS Foundation Trust. Regression analyses were carried out to determine factors associated with changes in HDL-C. RESULTS Linear regression analysis revealed that HDL-C change was associated with pretreatment HDL-C (P<0.001), diabetes (P=0.004) and treatment duration (P=0.036). Multiple regression analysis with all of the factors in the model suggested that they were independent. Patients with a baseline HDL-C <1.0 mmol/L showed a greater HDL-C increase when compared to patients with a baseline HDL-C ≥1.0 mmol/L; HDL-C <1.0 mmol/L (increase of 0.15 mmol/L, linear regression: c=0.14, 95% confidence interval 0.05-0.30, P<0.001) and HDL-C ≥1.0 (increase of 0.002 mmol/L, linear regression: reference category). A similar relationship between change in HDL-C and baseline HDL-C was observed within groups stratified by patient characteristics (apart from those on concurrent statin therapy and females). CONCLUSIONS Our results may explain the discrepancies observed in some randomized controlled trials whereby subgroup analysis of patients with the metabolic syndrome appeared to show benefit whereas this was absent in the total cohort. Thus, future interventional studies using fibrates should perhaps focus on patients with low HDL-C levels.
Collapse
Affiliation(s)
- Sud Ramachandran
- Department of Clinical Biochemistry, Heart of England NHS Foundation Trust, Sutton Coldfield, Birmingham, United Kingdom.
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
The high-pressure injection injuries are unusual injuries and the extent of tissue damage is often under estimated. They represent potentially disabling forms of trauma and have disastrous effects on tissues if not treated promptly. We present a case of high pressure injection injury to the finger from lubricant oil. The patient presented late with necrosis of volar tissue of left index finger. The patient was aggressively managed in stages, with delayed flap cover, with satisfactory functional and aesthetic outcome.
Collapse
Affiliation(s)
- Sanjay Saraf
- Department of Plastic Surgery, NMC Specialty Hospital, Dubai, UAE,Address for correspondence: Dr. Sanjay Saraf, Department of Plastic Surgery, NMC Specialty Hospital, Dubai, UAE. E-mail:
| |
Collapse
|
38
|
Abadie J, Abbott BP, Abbott R, Abernathy M, Accadia T, Acernese F, Adams C, Adhikari R, Ajith P, Allen B, Allen GS, Ceron EA, Amin RS, Anderson SB, Anderson WG, Antonucci F, Arain MA, Araya MC, Aronsson M, Arun KG, Aso Y, Aston SM, Astone P, Atkinson D, Aufmuth P, Aulbert C, Babak S, Baker P, Ballardin G, Ballmer S, Barker D, Barnum S, Barone F, Barr B, Barriga P, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Bastarrika M, Bauchrowitz J, Bauer TS, Behnke B, Beker MG, Belletoile A, Benacquista M, Bertolini A, Betzwieser J, Beveridge N, Beyersdorf PT, Bigotta S, Bilenko IA, Billingsley G, Birch J, Birindelli S, Biswas R, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bland B, Blom M, Boccara C, Bock O, Bodiya TP, Bondarescu R, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Bose S, Bosi L, Bouhou B, Boyle M, Braccini S, Bradaschia C, Brady PR, Braginsky VB, Brau JE, Breyer J, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Budzyński R, Bulik T, Bulten HJ, Buonanno A, Burguet-Castell J, Burmeister O, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Cain J, Calloni E, Camp JB, Campagna E, Campsie P, Cannizzo J, Cannon K, Canuel B, Cao J, Capano C, Carbognani F, Caride S, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cesarini E, Chalermsongsak T, Chalkley E, Charlton P, Chassande-Mottin E, Chelkowski S, Chen Y, Chincarini A, Christensen N, Chua SSY, Chung CTY, Clark D, Clark J, Clayton JH, Cleva F, Coccia E, Colacino CN, Colas J, Colla A, Colombini M, Conte R, Cook D, Corbitt TR, Cornish N, Corsi A, Costa CA, Coulon JP, Coward DM, Coyne DC, Creighton JDE, Creighton TD, Cruise AM, Culter RM, Cumming A, Cunningham L, Cuoco E, Dahl K, Danilishin SL, Dannenberg R, D'Antonio S, Danzmann K, Das K, Dattilo V, Daudert B, Davier M, Davies G, Davis A, Daw EJ, Day R, Dayanga T, De Rosa R, DeBra D, Degallaix J, del Prete M, Dergachev V, DeRosa R, DeSalvo R, Devanka P, Dhurandhar S, Di Fiore L, Di Lieto A, Di Palma I, Di Paolo Emilio M, Di Virgilio A, Díaz M, Dietz A, Donovan F, Dooley KL, Doomes EE, Dorsher S, Douglas ESD, Drago M, Drever RWP, Driggers JC, Dueck J, Dumas JC, Eberle T, Edgar M, Edwards M, Effler A, Ehrens P, Engel R, Etzel T, Evans M, Evans T, Fafone V, Fairhurst S, Fan Y, Farr BF, Fazi D, Fehrmann H, Feldbaum D, Ferrante I, Fidecaro F, Finn LS, Fiori I, Flaminio R, Flanigan M, Flasch K, Foley S, Forrest C, Forsi E, Fotopoulos N, Fournier JD, Franc J, Frasca S, Frasconi F, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Friedrich D, Fritschel P, Frolov VV, Fulda P, Fyffe M, Galimberti M, Gammaitoni L, Garofoli JA, Garufi F, Gemme G, Genin E, Gennai A, Gholami I, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Giazotto A, Gill C, Goetz E, Goggin LM, González G, Gorodetsky ML, Gossler S, Gouaty R, Graef C, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Greverie C, Grosso R, Grote H, Grunewald S, Guidi GM, Gustafson EK, Gustafson R, Hage B, Hall P, Hallam JM, Hammer D, Hammond G, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Haughian K, Hayama K, Hayau JF, Hayler T, Heefner J, Heitmann H, Hello P, Heng IS, Heptonstall AW, Hewitson M, Hild S, Hirose E, Hoak D, Hodge KA, Holt K, Hosken DJ, Hough J, Howell EJ, Hoyland D, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Ingram DR, Inta R, Isogai T, Ivanov A, Jaranowski P, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kandhasamy S, Kanner JB, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim H, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kondrashov V, Kopparapu R, Koranda S, Kowalska I, Kozak D, Krause T, Kringel V, Krishnamurthy S, Krishnan B, Królak A, Kuehn G, Kullman J, Kumar R, Kwee P, Landry M, Lang M, Lantz B, Lastzka N, Lazzarini A, Leaci P, Leong J, Leonor I, Leroy N, Letendre N, Li J, Li TGF, Liguori N, Lin H, Lindquist PE, Lockerbie NA, Lodhia D, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lu P, Luan J, Lubinski M, Lucianetti A, Lück H, Lundgren AD, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Majorana E, Mak C, Maksimovic I, Man N, Mandel I, Mandic V, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Marx JN, Mason K, Masserot A, Matichard F, Matone L, Matzner RA, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIvor G, McKechan DJA, Meadors G, Mehmet M, Meier T, Melatos A, Melissinos AC, Mendell G, Menéndez DF, Mercer RA, Merill L, Meshkov S, Messenger C, Meyer MS, Miao H, Michel C, Milano L, Miller J, Minenkov Y, Mino Y, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Mohan M, Mohanty SD, Mohapatra SRP, Moraru D, Moreau J, Moreno G, Morgado N, Morgia A, Morioka T, Mors K, Mosca S, Moscatelli V, Mossavi K, Mours B, Mow-Lowry CM, Mueller G, Mukherjee S, Mullavey A, Müller-Ebhardt H, Munch J, Murray PG, Nash T, Nawrodt R, Nelson J, Neri I, Newton G, Nishizawa A, Nocera F, Nolting D, Ochsner E, O'Dell J, Ogin GH, Oldenburg RG, O'Reilly B, O'Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Page A, Pagliaroli G, Palladino L, Palomba C, Pan Y, Pankow C, Paoletti F, Papa MA, Pardi S, Pareja M, Parisi M, Pasqualetti A, Passaquieti R, Passuello D, Patel P, Pathak D, Pedraza M, Pekowsky L, Penn S, Peralta C, Perreca A, Persichetti G, Pichot M, Pickenpack M, Piergiovanni F, Pietka M, Pinard L, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Poggiani R, Postiglione F, Prato M, Predoi V, Price LR, Prijatelj M, Principe M, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Quetschke V, Raab FJ, Rabeling DS, Radke T, Radkins H, Raffai P, Rakhmanov M, Rankins B, Rapagnani P, Raymond V, Re V, Reed CM, Reed T, Regimbau T, Reid S, Reitze DH, Ricci F, Riesen R, Riles K, Roberts P, Robertson NA, Robinet F, Robinson C, Robinson EL, Rocchi A, Roddy S, Röver C, Rolland L, Rollins J, Romano JD, Romano R, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sakata S, Sakosky M, Salemi F, Sammut L, de la Jordana LS, Sandberg V, Sannibale V, Santamaría L, Santostasi G, Saraf S, Sassolas B, Sathyaprakash BS, Sato S, Satterthwaite M, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield RMS, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Searle AC, Seifert F, Sellers D, Sengupta AS, Sentenac D, Sergeev A, Shaddock DA, Shapiro B, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Singer A, Sintes AM, Skelton G, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Speirits FC, Sperandio L, Stein AJ, Stein LC, Steinlechner S, Steplewski S, Stochino A, Stone R, Strain KA, Strigin S, Stroeer AS, Sturani R, Stuver AL, Summerscales TZ, Sung M, Susmithan S, Sutton PJ, Swinkels B, Szokoly GP, Talukder D, Tanner DB, Tarabrin SP, Taylor JR, Taylor R, Thomas P, Thorne KA, Thorne KS, Thrane E, Thüring A, Titsler C, Tokmakov KV, Toncelli A, Tonelli M, Torre O, Torres C, Torrie CI, Tournefier E, Travasso F, Traylor G, Trias M, Trummer J, Tseng K, Turner L, Ugolini D, Urbanek K, Vahlbruch H, Vaishnav B, Vajente G, Vallisneri M, van den Brand JFJ, Van Den Broeck C, van der Putten S, van der Sluys MV, van Veggel AA, Vass S, Vaulin R, Vavoulidis M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Veltkamp C, Verkindt D, Vetrano F, Viceré A, Villar AE, Vinet JY, Vocca H, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Wanner A, Ward RL, Was M, Wei P, Weinert M, Weinstein AJ, Weiss R, Wen L, Wen S, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, White D, Whiting BF, Wilkinson C, Willems PA, Williams L, Willke B, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Yakushin I, Yamamoto H, Yamamoto K, Yeaton-Massey D, Yoshida S, Yu P, Yvert M, Zanolin M, Zhang L, Zhang Z, Zhao C, Zotov N, Zucker ME, Zweizig J. Directional limits on persistent gravitational waves using LIGO S5 science data. Phys Rev Lett 2011; 107:271102. [PMID: 22243300 DOI: 10.1103/physrevlett.107.271102] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2011] [Indexed: 05/31/2023]
Abstract
The gravitational-wave (GW) sky may include nearby pointlike sources as well as stochastic backgrounds. We perform two directional searches for persistent GWs using data from the LIGO S5 science run: one optimized for pointlike sources and one for arbitrary extended sources. Finding no evidence to support the detection of GWs, we present 90% confidence level (C.L.) upper-limit maps of GW strain power with typical values between 2-20×10(-50) strain(2) Hz(-1) and 5-35×10(-49) strain(2) Hz(-1) sr(-1) for pointlike and extended sources, respectively. The latter result is the first of its kind. We also set 90% C.L. limits on the narrow-band root-mean-square GW strain from interesting targets including Sco X-1, SN 1987A and the Galactic center as low as ≈7×10(-25) in the most sensitive frequency range near 160 Hz.
Collapse
Affiliation(s)
- J Abadie
- LIGO-California Institute of Technology, Pasadena, California 91125, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kenny C, Adhya S, Dworakowski R, Brickham B, Maccarthy P, Monaghan M, Guzzo A, Innocenti F, Vicidomini S, Lazzeretti D, Squarciotta S, De Villa E, Donnini C, Bulletti F, Guerrini E, Pini R, Bendjelid K, Viale J, Duperret S, Piriou V, Jacques D, Shahgaldi K, Silva C, Pedro F, Deister L, Brodin LA, Sahlen A, Manouras A, Winter R, Berjeb N, Cimadevilla C, Dreyfus J, Cueff C, Malanca M, Chiampan A, Vahanian A, Messika-Zeitoun D, Muraru D, Peluso D, Dal Bianco L, Beraldo M, Solda' E, Tuveri M, Cucchini U, Al Mamary A, Badano L, Iliceto S, Almuntaser I, King G, Norris S, Daly C, Ellis E, Murphy R, Erdei T, Denes M, Kardos A, Foldesi C, Temesvari A, Lengyel M, Bouzas Mosquera A, Broullon F, Alvarez-Garcia N, Peteiro J, Barge-Caballero G, Lopez-Perez M, Lopez-Sainz A, Castro-Beiras A, Luotolahti M, Luotolahti H, Kantola I, Viikari J, Andersen M, Ersboell M, Bro-Jeppesen J, Gustafsson F, Koeber L, Hassager C, Moller J, Coisne D, Diakov C, Vallet F, Lequeux B, Blouin P, Christiaens L, Esposito R, Santoro A, Schiano Lomoriello V, Raia R, Santoro C, De Simone G, Galderisi M, Sahlen A, Abdula G, Winter R, Kosmala W, Szczepanik-Osadnik H, Przewlocka-Kosmala M, Mysiak A, O' Moore-Sullivan T, Marwick T, Tan YT, Wenzelburger F, Leyva F, Sanderson J, Pichler P, Syeda B, Hoefer P, Zuckermann A, Binder T, Fijalkowski M, Koprowski A, Galaska R, Blaut K, Sworczak K, Rynkiewicz A, Lee S, Kim W, Jung L, Yun H, Song M, Ko J, Khalifa EA, Szymanski P, Lipczynska M, Klisieiwcz A, Hoffman P, Jorge C, Silva Marques J, Robalo Martins S, Calisto C, Mieiro M, Vieira S, Correia M, Carvalho De Sousa J, Almeida A, Nunes Diogo A, Park C, March K, Tillin T, Mayet J, Chaturvedi N, Hughes A, Di Bello V, Giannini C, Delle Donne M, De Sanctis F, Spontoni P, Cucco C, Corciu A, Grigoratos C, Bogazzi F, Balbarini A, Enescu O, Suran B, Florescu M, Cinteza M, Vinereanu D, Higuchi Y, Iwakura K, Okamura A, Date M, Fujii K, Jorge C, Cortez-Dias N, Silva D, Carrilho-Ferreira P, Silva Marques J, Magalhaes A, Ribeiro S, Goncalves S, Fiuza M, Pinto F, Jorge C, Cortez-Dias N, Silva D, Silva Marques J, Carrilho-Ferreira P, Placido R, Bordalo A, Goncalves S, Fiuza M, Pinto F, Grzywocz P, Mizia-Stec K, Chudek J, Gasior Z, Maceira Gonzalez AM, Cosin Sales J, Dalli E, Igual B, Diago J, Aguilar J, Ruvira J, Cimino S, Pedrizzetti G, Tonti G, Canali E, Petronilli V, Boccalini F, Mattatelli A, Hiramoto Y, Iacoboni C, Agati L, Trifunovic D, Ostojic M, Vujisic-Tesic B, Petrovic M, Nedeljkovic I, Banovic M, Boricic-Kostic M, Draganic G, Tesic M, Petrovic M, Gavina C, Lopes R, Lourenco A, Almeida J, Rodrigues J, Pinho P, Zamorano J, Leite-Moreira A, Rocha-Goncalves F, Clavel MA, Capoulade R, Dumesnil J, Mathieu P, Despres JP, Pibarot P, Bull S, Pitcher A, Augustine D, D'arcy J, Karamitsos T, Rai A, Prendergast B, Becher H, Neubauer S, Myerson S, Magne J, Donal E, Davin L, O'connor K, Pirlet C, Rosca M, Szymanski C, Cosyns B, Pierard L, Lancellotti P, Calin A, Rosca M, Popescu B, Beladan C, Enache R, Lupascu L, Sandu C, Lancellotti P, Pierard L, Ginghina C, Kamperidis V, Hadjimiltiadis S, Sianos G, Anastasiadis K, Grosomanidis V, Efthimiadis G, Karvounis H, Parharidis G, Styliadis I, Gonzalez Canovas C, Munoz-Esparza C, Bonaque Gonzalez J, Fernandez A, Salar Alcaraz M, Saura Espin D, Pinar Bermudez E, Oliva-Sandoval M, De La Morena Valenzuela G, Valdes Chavarri M, Dreyfus J, Brochet E, Lepage L, Attias D, Cueff C, Detaint D, Himbert D, Iung B, Vahanian A, Messika-Zeitoun D, Pirat B, Little S, Chang S, Tiller L, Kumar R, Zoghbi W, Lee APW, Hsiung M, Wan S, Wong R, Luo F, Fang F, Xie J, Underwood M, Sun J, Yu C, Jansen R, Tietge W, Sijbrandij K, Cramer M, De Heer L, Kluin J, Chamuleau SAJ, Oliveras Vila T, Ferrer Sistach E, Delgado Ramis L, Lopez Ayerbe J, Vallejo Camazon N, Gual Capllonch F, Garcia Alonso C, Teis Soley A, Ruyra Baliarda X, Bayes Genis A, Negrea S, Alexandrescu C, Bourlon F, Civaia F, Dreyfus G, Paetzold S, Luha O, Hoedl R, Stoschitzky G, Pfeiffer K, Zweiker D, Pieske B, Maier R, Sevilla T, Revilla A, Lopez J, Vilacosta I, Arnold R, Gomez I, San Roman J, Nikcevic G, Djordjevic Dikic A, Djordjevic S, Raspopovic S, Jovanovic V, Kircanski B, Pavlovic S, Milasinovic G, Ruiz-Zamora I, Cabrera Bueno F, Molina M, Fernandez-Pastor J, Pena J, Linde A, Barrera A, Alzueta J, Bremont C, Bensaid A, Alonso H, Zaghden O, Nahum J, Dubois-Rande J, Gueret P, Lim P, Lee SP, Park K, Kim HR, Lee JH, Ahn HS, Kim JH, Kim HK, Kim YJ, Sohn DW, Niemann M, Herrmann S, Hu K, Liu D, Beer M, Ertl G, Wanner C, Takenaka T, Tei C, Weidemann F, Silva D, Madeira H, Mendes Pedro M, Nunes Diogo A, Brito D, Schiano Lomoriello V, Ippolito R, Santoro A, Esposito R, Raia R, De Palma D, Galderisi M, Gati S, Oxborough D, Reed M, Zaidi A, Ghani S, Sheikh N, Papadakis M, Sharma S, Chow V, Ng A, Pasqualon T, Zhao W, Hanzek D, Chung T, Yeoh T, Kritharides L, Florescu M, Magda L, Enescu O, Mihalcea D, Suran B, Jinga D, Mincu R, Cinteza M, Vinereanu D, Ferrazzi E, Segato G, Folino F, Famoso G, Senzolo M, Bellu R, Corbetti F, Iliceto S, Tona F, Azevedo O, Quelhas I, Guardado J, Fernandes M, Pereira V, Medeiros R, Lourenco A, Sousa P, Santos W, Pereira S, Marques N, Mimoso J, Marques V, Jesus I, Rustad L, Nytroen K, Gullestad L, Amundsen B, Aakhus S, Linhartova K, Sterbakova G, Necas J, Kovalova S, Cerbak R, Nelassov N, Korotkijan N, Shishkina A, Gagieva B, Nagaplev M, Eroshenko O, Morgunov M, Parmon S, Velthuis S, Van Gent M, Post M, Westermann C, Mager J, Snijder R, Koyalakonda SP, Anderson M, Burgess M, Bergenzaun L, Chew M, Ohlin H, Gjerdalen GF, Hisdal J, Solberg E, Andersen T, Radunovic Z, Steine K, Rutz T, Kuehn A, Petzuch K, Pekala M, Elmenhorst J, Fratz S, Mueller J, Hager A, Hess J, Vogt M, Van Der Linde D, Van De Laar I, Wessels M, Bekkers J, Moelker A, Tanghe H, Van Kooten F, Oldenburg R, Bertoli-Avella A, Roos-Hesselink J, Cresti A, Fontani L, Calabria P, Capati E, Severi S, Lynch M, Saraf S, Sandler B, Yoon S, Kim S, Ko C, Ryu S, Byun Y, Seo H, Ciampi Q, Rigo F, Pratali L, Gherardi S, Villari B, Picano E, Sicari R, Celutkiene J, Zakarkaite D, Skorniakov V, Zvironaite V, Grabauskiene V, Sinicyna J, Gruodyte G, Janonyte K, Laucevicius A, O'driscoll J, Schmid K, Marciniak A, Saha A, Gupta S, Smith R, Sharma R, Bouzas Mosquera A, Alvarez Garcia N, Peteiro J, Broullon F, Prada O, Rodriguez Vilela A, Barge Caballero G, Lopez Perez M, Lopez Sainz A, Castro Beiras A, Kochanowski J, Scislo P, Piatkowski R, Grabowski M, Marchel M, Roik M, Kosior D, Opolski G, Van De Heyning CM, Magne J, O'connor K, Mahjoub H, Pibarot P, Pirlet C, Pierard L, Lancellotti P, Clausen H, Basaggianis C, Newton J, Del Pasqua A, Carotti A, Di Carlo D, Cetrano E, Toscano A, Iacobelli R, Esposito C, Chinali M, Pongiglione G, Rinelli G, Larsson M, Larsson M, Bjallmark A, Winter R, Caidahl K, Brodin L, Velthuis S, Van Gent M, Mager J, Westermann C, Snijder R, Post M, Gao H, Coisne D, Lugiez M, Guivier C, Rieu R, D'hooge J, Lugiez M, Hang G, D'hooge J, Guerin C, Christiaens L, Menard M, Voigt JU, Coisne D, Dungu J, Campos G, Jaffarulla R, Gomes-Pereira S, Sutaria N, Baker C, Nihoyannopoulos P, Bellamy M, Adhya S, Harries D, Walker N, Pearson P, Reiken J, Batteson J, Kamdar R, Murgatroyd F, Monaghan M, D'andrea A, Riegler L, Scarafile R, Pezzullo E, Salerno G, Bossone E, Limongelli G, Russo M, Pacileo G, Calabro' R, Kang Y, Cui J, Chen H, Pan C, Shu X, Kiotsekoglou A, Saha S, Toole R, Govind S, Gopal A, Crispi F, Bijnens B, Sepulveda-Swatson E, Rojas-Benavente J, Dominguez J, Illa M, Eixarch E, Sitges M, Gratacos E, Prinz C, Faludi R, Walker A, Amzulescu M, Gao H, Uejima T, Fraser A, Voigt J, Esmaeilzadeh M, Maleki M, Amin A, Vakilian F, Noohi F, Ojaghi Haghighi Z, Nakhostin Davari P, Bakhshandeh Abkenar H, Rimbas R, Dulgheru R, Margulescu A, Florescu M, Vinereanu D, Toscano A, Chinali M, D' Asaro M, Iacobelli R, Del Pasqua A, Esposito C, Mizzon C, Parisi F, Pongiglione G, Rinelli G, Jung BC, Lee BY, Kang HJ, Kim S, Kim M, Kim Y, Cho D, Park S, Hong S, Lim D, Shim W, Bellsham-Revell H, Tibby S, Bell AJ, Miller OI, Greil G, Simpson JM, Providencia RA, Trigo J, Botelho A, Gomes P, Seca L, Barra S, Faustino A, Costa G, Quintal N, Leitao-Marques A, Nestaas E, Stoylen A, Fugelseth D, Mornos C, Ionac A, Petrescu L, Cozma D, Dragulescu D, Mornos A, Pescariu S, Fontana A, Abbate M, Cazzaniga M, Giannattasio C, Trocino G, Laser K, Faber L, Fischer M, Koerperich H, Kececioglu D, Elnoamany MF, Dawood A, Elhabashy M, Khalil Y, Fontana A, Abbate M, Cazzaniga M, Giannattasio C, Trocino G, Piriou N, Warin-Fresse K, Caza M, Fau G, Crochet D, Xhabija N, Allajbeu I, Petrela E, Heba M, Barreiro Perez M, Martin Fernandez M, Renilla Gonzalez A, Florez Munoz J, Fernandez Cimadevilla O, Alvarez Pichel I, Velasco Alonso E, Leon Duran D, Benito Martin E, Secades Gonzalez S, Gargani L, Pang P, Davis E, Schumacher A, Sicari R, Picano E, Silva Ferreira A, Bettencourt N, Matos P, Oliveira L, Almeida A, Maceira Gonzalez AM, Cosin-Sales J, Igual B, Lopez Lereu M, Monmeneu J, Estornell J, Tsverava M, Tsverava D, Varela A, Salagianni M, Galani I, Andreakos E, Davos C, Ikonomidis I, Lekakis J, Tritakis V, Kadoglou N, Papadakis J, Trivilou P, Tzortzis S, Koukoulis C, Paraskevaidis I, Anastasiou-Nana M, Kim G, Youn H, Park C, Ibrahimi P, Bajraktari G, Jashari F, Ahmeti A, Poniku A, Haliti E, Henein M, Pezo Nikolic B, Jurin H, Lovric D, Baricevic Z, Ivanac Vranesic I, Lovric Bencic M, Ernst A, Separovic Hanzevacki J. Poster Session 3: Friday 9 December 2011, 08:30-12:30 * Location: Poster Area. European Journal of Echocardiography 2011. [DOI: 10.1093/ejechocard/jer214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
40
|
Saraf S, Fridman D, Wagner J. Single-Incision Laparoscopic Gynecological Surgeries: 1 Year Experience. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Fridman D, Saraf S, Wagner J. Single-Incision Laparoscopy as the Primary Approach to Benign Hysterectomy: One Year Experience. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
42
|
|
43
|
Anand A, Pundir R, Pandian CS, Saraf S, Gupta H. Cefoperazone sodium impregnated polycaprolactone composite implant for osteomyelitis. Indian J Pharm Sci 2011; 71:377-81. [PMID: 20502542 PMCID: PMC2865808 DOI: 10.4103/0250-474x.57285] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2008] [Revised: 07/03/2009] [Accepted: 07/04/2009] [Indexed: 11/05/2022] Open
Abstract
The use of local antibiotics from a biodegradable implant for chronic osteomyelitis is an attractive alternative. The implant delivers high antibiotic concentration at tissue levels, obliterates dead space, aids bone repair and does not need to be removed. The purpose of this paper is to develop and evaluate a calcium sulphate and polycaprolactone based composite biodegradable implantable delivery system of cefoperazone sodium. Implants were prepared by modified fabrication technique to avoid solvent use. Interaction studies were carried out to check any incompatibility between ingredients. Prepared implants were evaluated for various in vitro parameters like dimensions, hardness, tensile strength, drug release profile and sterility. Morphological changes in pellet before and after drug release were evaluated by scanning electron microscopy. The pellet were also tested for microbiological efficacy and compared with plain drug solution in different concentrations. Developed pellets are regular in shape and size with good tensile strength. The release profile displayed drug levels above MIC continuously up to 2 months. Wide zone of inhibition by pellet against Staph. aureus as compared to drug solution proves its efficacy in treatment of osteomyelitis.
Collapse
Affiliation(s)
- A Anand
- Babu Banarasi Das National Institute of Technology & Management, Lucknow-226 007, India
| | | | | | | | | |
Collapse
|
44
|
Affiliation(s)
- Sanjay Saraf
- Department of Plastic Surgery, NMC Specialty Hospital, Dubai, U.A.E. E-mail:
| |
Collapse
|
45
|
Saraf S, Singh K. P162. Unusual case report of a malignant soft tissue tumor with review on emerging newer trends in histopathological diagnosis. Oral Oncol 2011. [DOI: 10.1016/j.oraloncology.2011.06.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Saraf S, Kharbanda J. O67. A rare case report of an adenomatoid odontogenic tumor arising in the wall of an odontogenic keratocyst. Oral Oncol 2011. [DOI: 10.1016/j.oraloncology.2011.06.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Abstract
Post-axial polydactyly is a common congenital hand anomaly with a wide range of manifestations. We report here an unusual case of intra-natal torsion of duplicated small finger which presented as gangrene at birth.
Collapse
Affiliation(s)
- Sanjay Saraf
- Department of Plastic Surgery, NMC Specialty Hospital, Dubai, UAE
| |
Collapse
|
48
|
Ramachandran S, Saraf S, Shetty C, Capps N, Bailey C. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Ann Clin Biochem 2010; 48:75-8. [PMID: 21115572 DOI: 10.1258/acb.2010.010081] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Statins are agents widely used to lower LDL-cholesterol (LDL-C) in primary and secondary prevention of coronary heart disease. The five statins available in the UK (simvastatin, pravastatin, fluvastatin, atorvastatin and rosuvastatin) differ in many of their pharmacologic properties. In addition to lowering LDL-C, statins also increase HDL-cholesterol (HDL-C) moderately. There have been rare reports of significant HDL-C decreases in patients commenced on fibrates and when thiazolidinediones are added to fibrates. This is known as a 'paradoxical HDL-C decrease' as both groups of agents usually increase HDL-C. This phenomenon has never been clearly documented following statin therapy. We now describe a patient with type 2 diabetes who showed this paradoxical fall in HDL-C (baseline HDL-C: 1.8 mmol/L; on simvastatin 40 mg HDL-C 0.6 mmol/L; on atorvastatin 20 mg HDL-C 0.9 mmol/L) with a similar decrease in apolipoprotein A1. No similar decrease was observed with pravastatin and rosuvastatin therapy. This phenomenon appeared to be associated with statin treatment and not a statin/fibrate combination. Our patient clearly demonstrated a paradoxical HDL-C fall with simvastatin and atorvastatin, but not pravastatin or rosuvastatin. Simvastatin and atorvastatin share many pharmacokinetic properties such as lipophilicity while pravastatin and rosuvastatin are relatively hydrophilic and are not metabolized by cytochrome P450 3A4. However, these characteristics do not explain the dramatic reductions in HDL-C observed.
Collapse
Affiliation(s)
- S Ramachandran
- Department of Clinical Biochemistry, Good Hope Hospital, Heart of England Foundation Trust, Sutton Coldfield, West Midlands, UK.
| | | | | | | | | |
Collapse
|
49
|
Saraf S. Moist exposed burn ointment: role of alternative therapy in the management of partial-thickness burns. Indian J Dermatol Venereol Leprol 2010; 76:415-7. [PMID: 20657129 DOI: 10.4103/0378-6323.66589] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
50
|
Affiliation(s)
- Sanjay Saraf
- Department of Plastic Surgery, NMC Speciality Hospital, Dubai, UAE
| | | |
Collapse
|